checkdown-arrowsearchshare

This site is intended for healthcare professionals outside the U.S.

The OTEZLA® International Website


close x

You are now leaving Otezla.net!


OTEZLA is an oral PDE4 inhibitor1

PDE4 inhibition helps restore balance in the immune system2

 

OTEZLA targets key intracellular signals to reduce inflammation2

  • Through intracellular PDE4 inhibition,OTEZLA reduces production of pro-inflammatory mediators and boosts production of anti-inflammatory mediators2
  • These mediators are implicated in the pathogenesis of psoriasis and psoriatic arthritis1,2
otezla treatment over time on production of selected cytokines
how otezla works through pde4 inhibition

PDE4 is a key inflammatory mediator2

  • PDE4 is active in immune cells, keratinocytes and synovial cells
  • PDE4 converts cAMP to AMP, which increases pro-inflammatory signaling
otezla is an oral pde4 inhibitor

OTEZLA is an oral PDE4 inhibitor1,2

  • By blocking PDE4, intracellular levels of cAMP increase
  • Higher levels of cAMP lead to balanced immune signaling
otezla restores balance to immune signaling

Blocking PDE4 restores balance to immune signaling2

  • Decreased production of pro-inflammatory mediators
  • Increased production of anti-inflammatory mediators

Impact of OTEZLA on production of selected cytokines3

OTEZLA has a unique MOA in psoriatic arthritis1

 

IFN, interferon; IL, interleukin; PDE4, phosphodiesterase-4; TNF, tumor necrosis factor.

References: 1. OTEZLA Summary of Product Characteristics. Stockley Park, Uxbridge, UK: Celgene Europe, Ltd; 2016. 2. Schafer PH, Parton A, Capone L, et al. Apremilast is a selective PDE4 inhibitor with regulatory effects on innate immunity. Cell Signal. 2014;26(9):2016-2029. 3. Schafer PH, Chen P, Fang L, et al. The Pharmacodynamic Impact of Apremilast, an Oral Phosphodiesterase 4 Inhibitor, on Circulating Levels of In ammatory Biomarkers in Patients with Psoriatic Arthritis: Substudy Results from a Phase III, Randomized, Placebo-Controlled Trial (PALACE 1). Journal of Immunology Research. 2015.


Select an e-mail client to share

close x